Table 3 Subgroup analysis in studies stratified by pregabalin dose
Subgroup | No. of arms | Sample size | Mean difference or risk ratio (95% CI) | Test for subgroup differences |
|---|---|---|---|---|
(pregabalin/placebo) | (P value) | |||
Static pain intensity at 24 h | ||||
≥ 150 mg/day | 2 | 70/52 | 0.04 [− 0.40, 0.47] | 0.3 |
< 150 mg/day | 9 | 240/241 | − 0.22 [− 0.46, 0.01] | |
Dynamic pain intensity at 24 h | ||||
≥ 150 mg/day | 3 | 97/94 | − 0.26 [− 0.89, 0.37] | 0.72 |
< 150 mg/day | 7 | 180/185 | − 0.41 [− 0.91, 0.08] | |
Morphine consumption within 24 h | ||||
≥ 150 mg/day | 2 | 126/122 | − 44.06 [− 96.28, 8.16] | 0.62 |
< 150 mg/day | 8 | 304/301 | − 30.12 [− 47.65, − 12.60] | |
Nausea | ||||
≥ 150 mg/day | 6 | 330/334 | 0.77 [0.60, 0.99] | 0.77 |
< 150 mg/day | 9 | 359/366 | 0.72 [0.50, 1.04] | |
Vomiting | ||||
≥ 150 mg/day | 4 | 272/276 | 0.77 [0.49, 1.21] | 0.99 |
< 150 mg/day | 6 | 276/277 | 0.78 [0.44, 1.37] | |
Drowsiness | ||||
≥ 150 mg/day | 3 | 154/156 | 1.43 [1.02, 1.98] | 0.05 |
< 150 mg/day | 4 | 339/340 | 0.95 [0.76, 1.19] | |
Dizziness | ||||
≥ 150 mg/day | 3 | 232/238 | 1.54 [1.02, 2.31] | 0.73 |
< 150 mg/day | 5 | 248/250 | 1.70 [1.13, 2.57] | |